Business / Finance

RSS

CD&R affiliate to acquire EMSC

Emergency Medical Services Corporation and Clayton, Dubilier & Rice, LLC (CD&R) announced today a definitive merger agreement under which an affiliate of CD&R formed to complete the merger will acquire EMSC. Under the terms of the agreement EMSC stockholders would receive, at the closing of the transaction, $64.00 in cash for each share of EMSC Class A common stock and Class B common stock and each LP Exchangeable Unit.

14 Feb 2011

Numira acquires Ricerca' Efficacy Pharmacology operating unit

Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, announced today that it has acquired the Efficacy Pharmacology operating unit of Ricerca Biosciences, LLC., located in Bothell, WA.

14 Feb 2011

ArthroCare fourth quarter total revenue increases to $92.6 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the fourth quarter and year ended December 31, 2010.

14 Feb 2011

Elite third quarter consolidated revenues increase 34% to $1.2 million

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal third quarter ended December 31, 2011.

14 Feb 2011

SynthRx to become wholly-owned subsidiary of ADVENTRX

ADVENTRX Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to acquire SynthRx, Inc., a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188.

14 Feb 2011

Meda's 2010 group sales decrease to SEK 11,571 million

“The Meda Group expects to achieve sales of about SEK 11,400 million and an EBITDA of about SEK 4,400 million.”

14 Feb 2011

Vitalitec announces acquisition of Novare's ENCLOSE II Anastomosis Assist Device

Vitalitec International, Plymouth, Massachusetts, is pleased to announce the acquisition of the ENCLOSE II Anastomosis Assist Device from Novare Surgical Systems. The ENCLOSE II Anastomosis Assist Device was developed by Thomas Fogarty, MD, and is designed to assist surgeons in performing "off pump" Coronary Artery Bypass Procedures.

14 Feb 2011

Sonoma acquires NovaLign Orthopaedics

Sonoma Orthopedic Products announced that it has completed the acquisition of certain key assets of NovaLign Orthopaedics, Inc.

14 Feb 2011

Optimer prices underwritten public offering of common stock

Optimer Pharmaceuticals, Inc. today announced the pricing of a previously announced underwritten public offering of 6,000,000 shares of its common stock, offered at a price to the public of $11.25 per share. The gross proceeds to Optimer from this offering are expected to be $67.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Optimer.

11 Feb 2011

Cyanotech third quarter revenues decrease to $3,919,000

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the third quarter and first nine months of fiscal 2011, ended December 31, 2010.

11 Feb 2011

GE Capital supports eBioscience with $55 million in senior secured credit facilities

GE Capital, Healthcare Financial Services announced today that it is agent and a lender for $55 million in senior secured credit facilities for eBioscience, Inc. The credit facilities will be used to finance the company's repurchase of certain shares from early investors, refinance existing debt, and provide growth capital.

11 Feb 2011

UFRF files lawsuit against Diamyd Medical

The University of Florida Research Foundation Inc. (UFRF) has filed a lawsuit in United States federal district court in Florida against Diamyd Medical claiming that UFRF is entitled to a percentage of the license fee paid to Diamyd Medical by Ortho-McNeil-Jansen Pharmaceuticals, Inc. (OMJPI).

11 Feb 2011

SeraCare first quarter revenue decreases 7% to $10.5 million

SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its first quarter of fiscal year 2011, ended December 31, 2010.

11 Feb 2011

AcelRx prices initial public offering at $5.00 per share

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at $5.00 per share. All of the common stock will be sold by AcelRx.

11 Feb 2011

Sorin's 2010 consolidated revenues increase 4.9% to € 745.8 million

The Board of Directors of Sorin S.p.A. meeting today under the chairmanship of Rosario Bifulco reviewed the fourth quarter 2010 and the preliminary 2010 consolidated results.

11 Feb 2011

Bradmer Pharmaceuticals records net loss of $117,000 for fourth quarter of 2010

Bradmer Pharmaceuticals Inc. today announced its 2010 fourth quarter and fiscal year operational and financial results.

10 Feb 2011

Agilent Technologies acquires specific assets of A2 Technologies

Agilent Technologies Inc. has completed the acquisition of specific assets of A2 Technologies. Financial details were not disclosed for the acquisition, which was first announced Jan. 19.

10 Feb 2011

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Valeant Pharmaceuticals International, Inc. today announced that its subsidiary, Biovail Laboratories International SRL, has acquired the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation.

10 Feb 2011

NeoGenomics fourth quarter revenue increases 12% to $8.8 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter 2010 and fiscal year ended December 31, 2010.

10 Feb 2011

Momenta reports fourth quarter 2010 net income of $36.3M vs. $14.7M net loss for fourth quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the fourth quarter and year ended December 31, 2010.

10 Feb 2011